Do Patents Kill Innovation?
Do
patents kill innovation? Evidence is piling up that they do. This time the
evidence is from the pharmaceutical industry itself. The strongest case for
patent has been made out in the pharmaceutical industry. Since pharmaceutical
research is inherently risky and requires substantial investment, it is argued
that the sector requires a strong patent protection.
It is in cancer drug discovery that evidence has come out that patents destroy R&D.
A paper, “Do fixed patent
terms distort innovation? Evidence from cancer clinical trials” by Eric Budish
of University of Chicago, Benjamin N. Roin of Harvard Law School and Heidi
Williams of MIT demonstrates, through empirical study, how patent system distorts
R&D for cancer therapy. The paper finds that patents generate distorted
R&D incentives, in the case of cancer. Cancer research, particularly for
early stage cancer, which is curable, requires long clinical trials. Therefore
industry prefers to invest in R&D for metastatic cancers, which requires
less duration trials, but the therapy may prolong the life by only a few months.
This is of significant concern from a medical perspective.
Surprisingly,
the authors note that there has been no empirical study on patent protection
and innovation.
Although theoretical models often assume a relationship
between the strength of patent protection and the level of innovation, there is
a remarkable dearth of empirical evidence on this link. For example, Lerner (2002) and Sakakibara and Branstetter (2001)
find little evidence that stronger intellectual property rights induce more
innovation.
Patent
exclusivity is for a limited period of 20 years. There is usually a
considerable gap between the filing of patent of the invention and the ultimate
commercialisation. This may be referred to as a commercialisation lag. Normally
for a drug the commercialisation lag is estimated to be about 10-12 years.
Firms have to recoup their research investment and the profit during the patent
period.
Cancer
has a paradox from a patent perspective. The survival has to be measured over
long periods of time. To explain, let us understand the two types of cancer.
When it starts cancer is mostly localized (the primary site). At this stage it
could be curable in many cases. At an advanced stage, the cancer spreads to
other parts of the body. Metastatic cancer is a cancer that has spread from the
primary site, where it started, to other parts of the body.
The
authors cite the example of two studies reported in New England Journal of
Medicine in 2011. A first study, de Bono et al. (2011), analyzed a treatment
for
metastatic
prostate cancer (an advanced stage of prostate cancer with a five-year survival
rate of the order of 20 percent). The study tracked patient survival for a
median time of 12.8 months, and estimated statistically significant
improvements in survival (a gain of 3.9 months of life on average). A second
study, Jones et al. (2011), analyzed a treatment for localized prostate cancer
(an early stage of prostate cancer with a five-year survival rate of the order
of 80 percent. The study tracked patient survival for a median time of 9.1
years, estimating statistically significant improvements in survival. Both the
above cases have different patient follow-up times and this translates into a
large difference in clinical trial length: 3 years for the metastatic cancer patient
trial versus 18 years for the localized patient trial.
A
private for profit firm will not carry out a trial for 18 years and bring a drug
to the market when patent term itself is 20 years. As may be expected, the authors
found that a private firm funded the study of the metastatic cancer patients
with the shorter duration trial whereas the National Cancer Institute funded
the study of localized cancer patients requiring long duration.
To
find a real cure for a primary cancer, R&D is required over long periods of
time. To demonstrate that cancer is cured, you need longer clinical trials with
long commercialisation lag. The ‘for profit’ firms have very little incentive
to do this. Therefore they focus on metastatic cancers that require only
shorter clinical trials, where cures would amount to prolonging the life by few
months.
Authors
of the paper analysed the data from a clinical trial registry that has
cataloged cancer clinical trials since the 1970s. They found the correlation
that privately financed trials favoured shorter survival terms. The authors
found that R&D investments on cancer treatments are strongly negatively
correlated with expected survival time. They observed lower levels of R&D
investment on inventions that required longer commercialization lags. This
coupled with corporate short
termism poses significant challenge to cancer research.
They
also found that all six FDA-approved cancer prevention drugs (that are
under-incentivized by the patent system), either relied on the use of surrogate
endpoints for shorter trials or were approved on the basis of publicly financed
clinical trials.
The
authors point out that in the pharmaceutical industry, “drugs treating patients
with short life expectancies can move through the clinical trials more quickly
-and thus receive longer effective patent terms - than drugs treating patients
with long life expectancies”. They provide several evidences showing patents
distorting cancer R&D away from drugs targeting early-stage cancer patients
or cancer prevention to late stage management.
In
essence, the innovation that happens is not what is medically mandated, but
driven by the industry’s ability to extract maximum during the patent term.
Another area where Patents are ineffective:
Neglected and Orphan Diseases
Patents
are a market driven tool. It works where there is a market from where it
enables recouping of investments. Where market is absent, patents do not
generate innovations.
Take
the case of orphan diseases and neglected diseases. Remember, the United States
is the largest pharmaceutical market of the world. Even there, if you have a
disease which does not command a huge market which interests pharmaceutical
companies, you don't have innovation. The Orphan
Drugs Act of US characterizes orphan diseases as those diseases that affect
small numbers of individuals residing in the United States that the diseases
and conditions are considered rare in the United States. It goes on to state
that:
·
because so few
individuals are affected by any one rare disease or condition, a pharmaceutical
company which develops an orphan drug may reasonably expect the drug to
generate relatively small sales in comparison to the cost of developing the
drug and consequently to incur a financial loss;
·
there is reason to
believe that some promising orphan drugs will not be developed unless changes
are made in the applicable Federal laws to reduce the costs of developing such
drugs and to provide financial incentives to develop such drugs; and
·
it is in the public
interest to provide such changes and incentives for the development of orphan
drugs.
This
enactment recognizes the limits of the patent system and therefore a policy instrument
other than patents have been used to spur innovation.
Compared
to the small number of patients affected by Orphan diseases, neglected diseases
affect a large number of individuals. Neglected Disease are mostly tropical
infectious diseases affecting a large number of people. They earn this
sobriquet as pharmaceutical companies generally neglect R&D in them. Take
the case of Tuberculosis (TB). TB is second only to HIV as the leading
infectious disease mortality, worldwide. 1.5 million people died of TB in 2012
alone. Someone dies of TB every 25 seconds somewhere in the world. Yet the
current drugs in use for TB hail from the 1950’s and 1960’s. The therapy is
lengthy and toxic. No new drugs that shorten the regimen have been introduced
despite the enormous progress made by pharmaceutical industry during this time;
that is the story of innovation for neglected diseases. TB is only
illustrative. Malaria, dengue fever, dracunculiasis, leishmaniasis, lymphatic
filariasis, onchocerciasis, schistosomiasis, soil transmitted helminthiasis, trachoma
and trypanosomiasis, so the list goes on, all affecting the poor in the
tropical regions. These diseases may be affecting different parts of the world.
But they have one thing in common – no innovation.
It
is in this sector that the 90-10 gap was noticed by the Commission on Health
Research for Development which published the report Health Research: Essential Link to
Equity in Development. 90% of the innovation in healthcare relates
to the diseases of a mere 10% of the population of the world. Pharmaceutical
companies who make substantial profits from global sale of drugs prefer
innovation in lifestyle diseases to that of neglected diseases.
Patents
as a public policy tool has completely failed to drive innovation in neglected
diseases.
Limits of the Patent System
All
these point to the limits of patent as an instrument of public policy to drive
innovation. It does not induce innovation in cancer nor does it in neglected or
orphan diseases. Patent induced innovation works only in a narrow space where
all other propitious conditions are present. Beyond this narrow market driven
space, say cancer or neglected diseases, it simply fails to drive innovation.
Patents
have been characterized by many as the ‘be all’ and ‘end all’ of innovation. There
are many who argue and even believe that patents are the sine qua non of
innovation. Provide the strictest of patent laws innovation will follow, so
goes the argument. This argument has been adopted, post TRIPS, by most
policymakers as a given.
But
the reality is different. It is only one of the components of a complex ecosystem
that makes up the innovation ecosystem. We have a tendency to assume many more
functions for patents.
Patents
perform a limited function. Patent system is a market based mechanism for capital
accumulation. It acts as an instrument to grant a limited exclusivity to the
innovator for a limited period. It does not fix other gaps in the innovation
ecosystem and its presence on its own does not spur innovation. On its own it
does not attract either innovation or technology or investment. A
counterfactual proves this assertion. If it was indeed the case, some of the
sub Saharan African nations who have the strongest of the patent laws should
have been the most innovative as well. In any case, post TRIPS we have more or
less uniform patent laws around the world but that has not spread innovation or
investment across the world.
Public
policy making is not always evidence based. That is the tragedy. It is most of
the time based on beliefs. And the predominant beliefs of the age always find
its place in the policies, without much evidence to support such beliefs, whether
good or bad. Sometimes evidence emerges to the contrary but they are ignored if
it is against the current belief.
Corporate
short termism and limits of patent puts a limit on humanities quest to find
cures for many diseases. There has to be other public policy instruments that would
drive and support innovation in cases where patent system does not work, or
worse, provide perverse innovation as in the case of cancer.
Call for Reform
Do
patents kill innovation? Even the conservative journal like The Economist
thinks so. The Economist has recognized the limitations of the patent system
and has called for reform. This is what the Economist
says:
A one-size-fits-all patent system does not cater to the
specifics of innovation in the pharmaceutical industry. But tailoring patent
law may encourage lobbying and corruption. A careful reform of the patent system is necessary: outright abolition of patents will not be enough to save
cancer patients’ lives.
In
2014, we are moving to 20 years of TRIPS. If many in the developing world ask,
“what have we gained”, there is very little to answer to them in terms of
better medicines for their diseases. If we accept that all lives have equal
value, it is time for policy makers to
take a comprehensive look at innovation in the pharmaceutical sector and abhor
the myopic view that patent cures all.